← Back to Search

Cortisol Synthesis Inhibitor and Benzodiazepine Receptor Agonist

EMB-001 for Tobacco Use Disorder

Phase 1 & 2
Waitlist Available
Research Sponsored by Embera NeuroTherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 9-12
Awards & highlights

Summary

This trial tests EMB-001, a combination of two drugs that reduce stress and anxiety, to help adult smokers quit smoking over a few months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 9-12
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 9-12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Smoking Abstinence

Trial Design

1Treatment groups
Experimental Treatment
Group I: EMB-001 ActiveExperimental Treatment1 Intervention
720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EMB-001
2016
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Foundation for a Smoke-Free WorldOTHER
9 Previous Clinical Trials
1,062 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
75 Patients Enrolled for Tobacco Use Disorder
Embera NeuroTherapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
203 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
49 Patients Enrolled for Tobacco Use Disorder
Foundation for a Smoke Free World INCOTHER
14 Previous Clinical Trials
2,133 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
75 Patients Enrolled for Tobacco Use Disorder
~4 spots leftby Sep 2025